|Last Price||Today's Change||52-Week Range||Trading Volume|
|117.60||0.22 (+0.19%)||83.16 - 140.72||3.3 million (Below Avg)|
Market data as of 3:59PM 10/12/15. Quotes are delayed by at least 15 min.
One Year Data from Phase III Study Evaluating Oral OTEZLA® (apremilast) or Injectable etanercept versus Placebo in Patients with Moderate to Severe Plaque Psoriasis Presented at EADV
10/12/2015 7:30 AM ET
LUNGevity Foundation and Celgene Team to Address Unmet Need
10/08/2015 8:45 AM ET